Liquidia (NASDAQ:LQDA) Director Sells $9,603,972.76 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 148,301 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $64.76, for a total value of $9,603,972.76. Following the transaction, the director owned 1,636,941 shares in the company, valued at approximately $106,008,299.16. This represents a 8.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Stock Up 1.9%

Shares of NASDAQ:LQDA traded up $1.24 during trading on Wednesday, hitting $65.25. The company’s stock had a trading volume of 2,327,936 shares, compared to its average volume of 1,722,392. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78. The stock’s 50-day moving average price is $47.90 and its two-hundred day moving average price is $40.11. The company has a market capitalization of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post 2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LQDA shares. Oppenheimer set a $75.00 price target on shares of Liquidia in a research report on Friday, June 5th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. HC Wainwright increased their target price on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Needham & Company LLC increased their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.63.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Farallon Capital Management LLC raised its position in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $38,887,000. Caprock Group LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $37,114,000. MPM Bioimpact LLC raised its position in shares of Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after purchasing an additional 1,200,869 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $12,571,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).